The level of serum Tumor Marker CA15-3 in women with Breast Cancer

Background: Breast cancer is the most frequently diagnosed type of cancer in women in all world regions. About 1.7 million cases of breast cancer are diagnosed every year. Breast cancer is the most common cause of death in women worldwide. There were approximately 0.5 million deaths worldwide from...

Full description

Bibliographic Details
Main Authors: Huda Hameed Othman, Walaa Najm Abood, Nazar Abdul Hassan Alwakeel
Format: Article
Language:English
Published: College of medicine/ University of Diyala 2018-10-01
Series:Diyala Journal of Medicine
Subjects:
Online Access:https://www.djm.uodiyala.edu.iq/index.php/djm/article/view/160
_version_ 1797586296924798976
author Huda Hameed Othman
Walaa Najm Abood
Nazar Abdul Hassan Alwakeel
author_facet Huda Hameed Othman
Walaa Najm Abood
Nazar Abdul Hassan Alwakeel
author_sort Huda Hameed Othman
collection DOAJ
description Background: Breast cancer is the most frequently diagnosed type of cancer in women in all world regions. About 1.7 million cases of breast cancer are diagnosed every year. Breast cancer is the most common cause of death in women worldwide. There were approximately 0.5 million deaths worldwide from breast cancer in 2012, several serum tumor markers have been evaluated in breast cancer. CA15-3 is the most important serum biomarkers used for diagnosis and monitoring of breast cancer. Objective: To evaluate the level of CA15-3 of studied groups according to age categories, residence nearby industries, and history of breast feeding. Patients and Methods: This study was carried out at the Breast Surgery Outpatients and the Oncology Clinic at Oncology Teaching Hospital in Baghdad. It included 50 women who were newly diagnosed by oncology group to have had breast cancer and didn’t receive chemotherapy yet and 50 healthy women as control. Results: There was significant increase at (P> 0.05) in serum CA15-3 level of patients with age category (71-80) years (198.33 ± 136.60 U/ml) and significant elevation in serum CA15-3 level of patients who lived near industries or incinerators (120 ± 94.52 U/ml) also there was significant increase in serum CA15-3 level in healthy women with breast feeding history (25.8 ± 15.26 U/ml). Conclusion: CA15-3 level significantly elevated in elderly patients with age category (71-80) years and in patients with residence nearby industries or incinerators. Therefore, those patients at high risk of developing metastatic breast cancer or advanced stages of breast cancer.
first_indexed 2024-03-11T00:21:19Z
format Article
id doaj.art-2f3edcd57daf4ccb8a323aad1aa5c4e4
institution Directory Open Access Journal
issn 2219-9764
2617-8982
language English
last_indexed 2024-03-11T00:21:19Z
publishDate 2018-10-01
publisher College of medicine/ University of Diyala
record_format Article
series Diyala Journal of Medicine
spelling doaj.art-2f3edcd57daf4ccb8a323aad1aa5c4e42023-11-18T23:18:01ZengCollege of medicine/ University of DiyalaDiyala Journal of Medicine2219-97642617-89822018-10-01151The level of serum Tumor Marker CA15-3 in women with Breast CancerHuda Hameed OthmanWalaa Najm AboodNazar Abdul Hassan Alwakeel Background: Breast cancer is the most frequently diagnosed type of cancer in women in all world regions. About 1.7 million cases of breast cancer are diagnosed every year. Breast cancer is the most common cause of death in women worldwide. There were approximately 0.5 million deaths worldwide from breast cancer in 2012, several serum tumor markers have been evaluated in breast cancer. CA15-3 is the most important serum biomarkers used for diagnosis and monitoring of breast cancer. Objective: To evaluate the level of CA15-3 of studied groups according to age categories, residence nearby industries, and history of breast feeding. Patients and Methods: This study was carried out at the Breast Surgery Outpatients and the Oncology Clinic at Oncology Teaching Hospital in Baghdad. It included 50 women who were newly diagnosed by oncology group to have had breast cancer and didn’t receive chemotherapy yet and 50 healthy women as control. Results: There was significant increase at (P> 0.05) in serum CA15-3 level of patients with age category (71-80) years (198.33 ± 136.60 U/ml) and significant elevation in serum CA15-3 level of patients who lived near industries or incinerators (120 ± 94.52 U/ml) also there was significant increase in serum CA15-3 level in healthy women with breast feeding history (25.8 ± 15.26 U/ml). Conclusion: CA15-3 level significantly elevated in elderly patients with age category (71-80) years and in patients with residence nearby industries or incinerators. Therefore, those patients at high risk of developing metastatic breast cancer or advanced stages of breast cancer. https://www.djm.uodiyala.edu.iq/index.php/djm/article/view/160Breast Cancer, Tumor Marker, CA15-3.
spellingShingle Huda Hameed Othman
Walaa Najm Abood
Nazar Abdul Hassan Alwakeel
The level of serum Tumor Marker CA15-3 in women with Breast Cancer
Diyala Journal of Medicine
Breast Cancer, Tumor Marker, CA15-3.
title The level of serum Tumor Marker CA15-3 in women with Breast Cancer
title_full The level of serum Tumor Marker CA15-3 in women with Breast Cancer
title_fullStr The level of serum Tumor Marker CA15-3 in women with Breast Cancer
title_full_unstemmed The level of serum Tumor Marker CA15-3 in women with Breast Cancer
title_short The level of serum Tumor Marker CA15-3 in women with Breast Cancer
title_sort level of serum tumor marker ca15 3 in women with breast cancer
topic Breast Cancer, Tumor Marker, CA15-3.
url https://www.djm.uodiyala.edu.iq/index.php/djm/article/view/160
work_keys_str_mv AT hudahameedothman thelevelofserumtumormarkerca153inwomenwithbreastcancer
AT walaanajmabood thelevelofserumtumormarkerca153inwomenwithbreastcancer
AT nazarabdulhassanalwakeel thelevelofserumtumormarkerca153inwomenwithbreastcancer
AT hudahameedothman levelofserumtumormarkerca153inwomenwithbreastcancer
AT walaanajmabood levelofserumtumormarkerca153inwomenwithbreastcancer
AT nazarabdulhassanalwakeel levelofserumtumormarkerca153inwomenwithbreastcancer